Skip to content

Phosphatidylethanol and Other Ethanol Consumption Markers

Phosphatidylethanol and Other Ethanol Consumption Markers

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06747364
Enrollment
80
Registered
2024-12-24
Start date
2025-01-07
Completion date
2029-06-30
Last updated
2025-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Consumption, Healthy Volunteer

Keywords

Healthy adult, Light, moderate and heavy drinkers

Brief summary

This study is intended to help the investigators understand how a biomarker found in the blood may be used to better identify the quantity and different patterns of alcohol use. The investigators hope that the results of this study will help identify the uses of alcohol-use markers in the blood in future alcohol prevention and treatment programs. It is hoped that the information learned from this study will benefit other people in the future. The study participants will come into the lab and will (1) consume alcohol in the lab designed to produce a peak blood alcohol concentration of 0.06% and have blood collected over 6 hours followed by abstinence for 10 days to give a small blood sample 4 times and (2) to give a small amount of blood 5 times within 28 days (naturalistic drinking) and provide answers about alcohol use.

Detailed description

The study goal is to account for individual differences in biological variables likely influencing Phosphatidylethanol (PEth) formation to determine the extent to which the investigators can improve their ability to characterize alcohol consumed previously. Investigators propose three experiments that combine: (a) controlled human laboratory studies in vivo, (b) clinical laboratory studies of important enzymatic and biological variables measured ex vivo, and (c) the creation and testing of regression models to predict drinking during a naturalistic observational study using PEth levels and key biological variables identified in the lab. Aim 1 is an in vivo pharmacokinetic study that whereby participants will consume a dose of alcohol to achieve a target blood alcohol concentration of 0.06%. Blood samples will be collected repeatedly during a 6-hour period to characterize blood/breath alcohol concentrations and PEth syntheses. Then PEth elimination half-life will be characterized across a 10-day period while remaining alcohol abstinent outside the lab. In Aim 2, alcohol-free blood collected from Aim 1 will be examined ex vivo to characterize key biological variables (e.g., enzyme activity, red blood cell count, precursor levels) involved in PEth synthesis and elimination. Regression formulas will evaluate these variables for their ability to explain the previously unexplained between-subject differences in the PEth levels formed after the same amount of alcohol is consumed. Finally, in Aim 3, regression equations will be used to evaluate the value of using these biological/enzyme variables to improve (above and beyond that of PEth alone) the prediction of naturalistic drinking self-reported by participants over a 28-day period.

Interventions

Alcohol will be administered to participants by research staff. In Phase 1, participants will consume alcohol designed to produce a targeted blood alcohol concentration (BAC) of 0.06% using the modified Widmark equation.

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
The University of Texas Health Science Center at San Antonio
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

The alcohol administration study will occur at the Applied Physiology Laboratory (APL) at UNT. The naturalistic drinking study will occur at UNT and a 2nd cohort will undergo a naturalistic drinking study at UTHSCSA Behavioral Research Lab (BRL).

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. are ≥ 21 years old; 2. are height and weight proportionate (body mass index 18-30); and 3. report drinking on \> 1 days in the last month, with at least one day equal to at least achieving \ 0.06% BAC.

Exclusion criteria

1. have significant current or predicted alcohol withdrawal symptoms (CIWA-AR scores ≥ 10); 2. are currently in alcohol treatment; 3. have substance use disorder (except nicotine, and/or caffeine); 4. have a medical condition that would contraindicate participation (a positive urine pregnancy test, self-reported scheduled surgery or liver disease); 5. are currently breast feeding; 6. have a presence of a DSM-5 psychiatric disorder with symptoms of psychosis and/or delirium; or 7. are unable to comprehend the informed consent process or study instructions.

Design outcomes

Primary

MeasureTime frameDescription
Phosphatidylethanol (PEth) concentrations on alcohol administration day in Males/FemalesBaseline to 360 minutesMeasure of PEth level in ng/ml over 360 minutes
Breath alcohol concentrations on alcohol administration day in Males/FemalesBaseline to 360 minutesMeasure of breath alcohol concentrations in g/dL over 360 minutes
PEth Concentrations for half-life in Males/FemalesEnd of Day 0 to 10 daysMeasure of PEth concentrations in ng/ml on days 0 (end of day), 3, 5, 7 and 10
PEth concentrations once weekly during 28 days naturalistic drinking in Males/FemalesBaseline to 28 daysMeasure of PEth level in ng/ml on days 0, 7, 14, 21 and 28
Self-reported drinking during the 28 days naturalistic drinking in Males/FemalesBaseline to 28 daysTLFB on days 0, 7, 14, 21 and 28
PEth Concentrations during the 28 days naturalistic drinking in Males/FemalesBaseline to 28 daysMeasure of PEth concentrations in ng/ml on days 0, 7, 14, 21 and 28
Red blood cell count (RBC) in Males/FemalesOne time (baseline)]Measurement of RBCs in cells/mm\^3
Phosphatidylcholine (PC) content in Males/FemalesOne time (baseline)Measurement of PC content in ng/ml at baseline
Ex vivo PEth formation for PLD activity in blood from Males/FemalesBaseline to 90 minutesPEth concentrations in ng/mL at 0, 15, 30, 45, 60, and 90 min after alcohol exposure

Countries

United States

Contacts

Primary ContactNathalie Hill-Kapturczak, PhD
Hillkapturcz@uthscsa.edu210-567-2725
Backup ContactDonald Dougherty, PhD
Donald.Dougherty@unt.edu940-565-2649

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026